A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
| 대상 질환 | Atopic Dermatitis |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Amgen |
| 상태 | 완료 |
| 참여자 수 | 187 명 |
| 중재(약물) | Rocatinlimab |
| 시작일 | 2023년 1월 30일 |
| 완료일 | 2025년 7월 31일 |
| 결과 공개일 | 2026년 7월 24일 |
요약
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)
| Rocatinlimab | 4 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen
- BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort — Women's College Hospital